Home / Quality Standards
Last reviewed: May 15, 2026 · Reviewed by Dr. Tshering Pedon
The question a Canadian researcher should be asking a peptide supplier in 2026 is no longer "what are your quality standards?" It's "how do I know your quality claims are real?" Health Canada's April 9 advisory, CBSA's active interception of unauthorized shipments, and the documented variation in COA quality across the broader research peptide market have all made the second question the one that matters. This page is built around answering it.
Koi Peptides Canada operates under a quality framework that has one defining feature: every analytical claim on every Certificate of Analysis is generated by an independent third-party laboratory and can be verified by the buyer against the lab's own records, without going through Koi. The rest of the framework, written specifications, compendial methods, batch retention, and non-conformance handling, exists to make that verification meaningful.
A Certificate of Analysis is only as good as the entity that issued it. This is the structural issue at the heart of the Canadian peptide market right now.
When a vendor's in-house lab issues a COA, the result and the conflict of interest sit in the same building. A failing purity test can be rerun. A high endotoxin reading can be quietly set aside. A chromatogram can be reformatted. None of this requires bad intent. Even competent labs face pressure to release material that is close to spec. The structural problem is that there is no external party with a stake in catching a discrepancy.
When an independent third-party lab issues the COA, that calculus changes. The result lives on the lab's own server, under the lab's verification ID, before the vendor ever sees it. A failing result generates a record outside the vendor's control. A reissued document under a new ID creates an audit trail. The buyer's ability to confirm the result against the lab directly is what turns "trust us" into "verify us."
Health Canada's April 9, 2026, advisory specifically called out the failure mode of unverifiable documentation in the unauthorized peptide market: products being shipped with COAs that buyers cannot confirm and for which no independent record exists. The verification problem isn't theoretical. It's the regulator's stated concern.
Koi's quality framework is structured around solving that problem, batch by batch.
Before any batch leaves the production side at Koi, it has to meet a written product specification. The specification exists before the analytical work begins, not after. It defines what an acceptable result looks like for each parameter, and the result of the test is compared against that written standard, not the other way around.
The standard specification for a Koi catalogue peptide covers six parameters:
| Parameter | Method | What an in-spec result looks like |
|---|---|---|
| Identity | Electrospray ionization mass spectrometry (ESI-MS) | Observed mass within ±1 Da of the theoretical monoisotopic mass on a quadrupole instrument |
| Purity | Analytical HPLC, reversed-phase, UV detection at 210 or 214 nm | ≥99% area percent under specified gradient conditions |
| Net peptide content | UV detection at 205 or 280 nm against calibrated standards | Numerical value per batch, traceable to the calibration method used |
| Bacterial endotoxin | USP <85> / Ph. Eur. 2.6.14 LAL assay | Numerical EU/mg result with method format specified |
| Residual solvents | Gas chromatography per ICH Q3C | Within ICH Q3C class 2 and class 3 limits where solvents are used in synthesis |
| Heavy metals | ICP-MS | Reported in parts per billion where catalysts are used in the synthesis route |
For peptides that need additional analytical characterization (modified residues, complex tertiary structure, applications where the buyer specifically requests it), the specification is extended, and that extension is recorded in the product master. The same extended specification is then applied to every batch of that compound, not on a per-order basis.
Two numbers on this list matter more than the others for most researchers. The HPLC purity tells you what fraction of the material in the vial is the target sequence. The endotoxin number tells you whether the material is clean enough for cell culture or any application that touches the immune system. Everything else is supporting context.
A test result is only as meaningful as the method behind it. This is where compendial methods earn their weight.
A compendial method is one that has been published in an established pharmacopeia, the United States Pharmacopeia (USP), the European Pharmacopeia (Ph. Eur.), or the Japanese Pharmacopeia (JP), as a validated procedure. Validation means the method's performance characteristics (accuracy, precision, specificity, detection limits) have been demonstrated and documented by the pharmacopoeial body. The framework for that validation work sits in USP General Chapter <1225>, "Validation of Compendial Procedures."
When a specific lab applies a compendial method, it is required to verify that the method works on its own instruments, with its own reagents, on the type of sample being tested. This is method verification, distinct from method validation, and the framework for it sits in USP General Chapter <1226>. Verification produces a record showing that the published method performs as intended in the specific conditions of use.
The independent lab that runs Koi's analytical panel maintains verification records for each compendial method it applies. Two things follow from this for a buyer reading a Koi COA.
The retention time on an HPLC chromatogram should be reproducible across batches of the same product, because the method behind it is verified and the system suitability checks are documented. A retention time that drifts noticeably between batches of the same compound suggests a method change or a material change, either of which the lab should have flagged.
An endotoxin result in EU/mg should be traceable to a recognized procedure with documented performance characteristics, not a proprietary in-house variant. USP <85> and Ph. Eur. 2.6.14 are harmonized internationally and recognized by Health Canada for the relevant applications. A number that comes out of a method outside that framework carries less weight in any due diligence review.
Koi sends samples from each synthesis batch to an independent analytical laboratory before the batch is released. The lab performs the testing on its own instruments, by its own staff, and issues the Certificate of Analysis under its own letterhead. The COA carries a unique verification ID per sample submission. Koi pays for the testing. The lab issues the result independently of that payment.
The verification ID is the linchpin of the model. It does three things simultaneously:
It connects the COA in the buyer's hand to a specific entry on the testing lab's own server. Anyone with the ID can confirm that the document is authentic by checking it against the lab directly.
It creates a record that exists outside Koi's control. If a batch fails, the failure shows up in the lab's records. Koi cannot retroactively "edit" a failing result because the result was never Koi's to begin with.
A Canadian researcher running an experiment in June 2026 who needs to confirm what was used when writing the manuscript in November 2027 can pull the original COA from Koi's archive and re-verify the ID against the testing lab's records, more than a year after the original sale.
Independent analytical labs operating in this space typically work under ISO/IEC 17025:2017, the international standard governing competence for testing and calibration laboratories. The standard covers personnel qualifications, equipment calibration, method validation records, sample handling, reporting practices, and the management system underneath all of it. For any Canadian researcher doing due diligence on a peptide supplier, asking whether the third-party lab holds 17025 accreditation is a standard question, and the answer should be a documented one.
Not every synthesis run produces material that meets the specification. Peptide chemistry at scale produces variation, and a quality framework that doesn't acknowledge this is a framework that quietly releases out-of-spec material. Koi's non-conformance protocol has three stages.
When a result falls outside the written specification, the testing is reviewed with the independent lab to confirm the result is real rather than an artifact of method or sample handling. The original analytical record is reviewed and, where appropriate, the sample is retested. If the retest confirms the original result, the batch enters the next stage.
The synthesis batch record is reviewed against the analytical result. A purity miss usually traces back to a coupling failure during synthesis, an incomplete cleavage, or a purification step that didn't adequately separate a closely related impurity. An elevated endotoxin reading usually traces to the water source, vessel contamination, or a specific handling step. The point of the root cause work isn't just to explain the current batch. It's to identify what needs to change in the next run.
A batch that fails specification is either reworked or rejected. Rework typically means a second preparative HPLC pass and a fresh analytical panel against the original specification. Rejection means the batch is removed from inventory, destroyed under a documented destruction record, and never released. The decision between rework and rejection depends on the failure mode. A purity miss by one or two percentage points is generally reworkable. A mass-spectrometry discrepancy that points to a sequence error is not.
The records generated through this protocol, investigation notes, root cause findings, disposition decision, and destruction confirmation are linked to the batch record and retained alongside the COA file. If a Canadian researcher ever asks why a specific catalogue SKU was unavailable in a specific month, the answer can be traced back to a specific batch and a specific decision.
The willingness to reject batches is the operational test of whether a written specification is real or decorative.
Every Koi synthesis lot generates a documentation chain that travels with the material for the life of the product. The chain has four pieces:
Generated at the time of synthesis. It captures the date, the operator, the resin lot, the amino acid lots, the coupling reagent lots, the in-process observations from coupling efficiency checks, and any deviations from the standard procedure. Retained against the lot number.
Generated by the independent testing lab. It includes the chromatographic trace, the mass spectrum, the endotoxin measurement, and any residual solvent or heavy metals data. The record is issued under the lab's verification ID and is retained on the lab's own server as well as in Koi's archive. Retained against the lot number.
Generated when the batch is approved for sale. It captures the side-by-side comparison of the analytical results against the written specification, the disposition decision, and the approval signature. This is the document that says "this batch met the spec and was released." Retained against the lot number.
A small physical portion of the batch, set aside under documented storage conditions for the operational life of the product. If a quality question arises about the lot after release, the retention sample is available for re-testing against the original analytical record. Storage conditions and chain of custody are documented from synthesis through retention.
These four pieces together constitute the full traceability dossier for a Koi synthesis lot. Any buyer with a lot number from a Koi vial can pull the COA through the COA Library on the Canadian site. Any auditor or regulator with appropriate authority can request the underlying batch record, analytical record, release record, and retention sample.
The functional point of the dossier is reproducibility. If a researcher uses Koi material in June 2026 and needs to defend the analytical profile of that exact material in November 2027 or later, the documentation is still there and still verifiable.
The research peptide market spans a wide range of operational tiers. Being honest about which tier a vendor operates in is part of trustworthy positioning.
Tier 1
Manufactured under Health Canada's Good Manufacturing Practices regulations as set out in Part C, Divisions 2 to 4 of the Food and Drug Regulations. These materials carry a Drug Establishment Licence (DEL) under Part C, Division 1A, full chain-of-custody documentation, sterile manufacturing environments where required, validated analytical methods filed with Health Canada, full ICH stability data, and clinical-grade documentation supporting human therapeutic use. Pharmaceutical suppliers like Bachem, PolyPeptide, and CordenPharma operate in this tier.
Koi does not operate at this tier.
Tier 2
Synthesized under written SOPs, tested against published specifications using compendial methods, with results issued by an independent laboratory and traceable to verifiable analytical records. Material in this tier is appropriate for in vitro and preclinical research, where verified analytical purity, identity, content, and endotoxin data are required.
This is the tier Koi operates in.
Tier 3
Tested in-house, and the COA is issued by the same organization that made the material. May be technically accurate. Cannot be verified against an external record without independently retesting the material.
Tier 4
Ship with generic product-level COAs, missing chromatograms, missing endotoxin data, or "Pass/Fail" indicators without numerical values. Functionally, this is the bottom of the market and the segment that Health Canada's April 9 advisory most directly addressed.
Tier 2 is where serious research-use sourcing in Canada should sit. It carries the analytical credibility that supports reproducible work without the pharmaceutical-grade regulatory burden that pharmaceutical-grade materials require. Koi's quality framework is designed specifically for the Tier 2 standard, and the framework's structural features, independent verification, compendial methods, written specifications, retention samples, and lot-level traceability exist to keep it there.
Koi does not hold a Drug Establishment Licence from Health Canada under Part C, Division 1A of the Food and Drug Regulations. Koi does not fabricate, package, label, distribute, import, wholesale, or test drugs for human use under the Canadian regulatory framework.
Koi's facility is not registered as a drug manufacturer under Health Canada's GMP requirements set out in Part C, Divisions 2 to 4 of the regulations. Koi does not produce material to pharmaceutical-grade specifications.
Koi is not a compounding pharmacy. Compounding for human use in Canada is regulated by provincial pharmacy regulatory authorities. Koi does not prepare patient-specific formulations and does not dispense without prescriptions.
Koi sells into the research-use framework as it was designed: laboratory work, in vitro studies, analytical research. Anything outside that scope sits outside what Koi supplies.
The verifiable artifacts of the Koi quality framework are:
The verification step itself is short. Take the lot number from the vial, pull the COA from the COA Library, take the verification ID from the COA, and check it against the testing lab's records. If the ID resolves to a result that matches the document, the COA is authentic. If it doesn't, Koi wants to know about it immediately and will investigate.
This is the verification model the Canadian research peptide market needs, and the model Koi Peptides Canada is built around from the start.
No account yet?
Create an Account
